ProShare Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $370K | Sell |
26,414
-2,208
| -8% | -$31K | ﹤0.01% | 1296 |
|
|
2025
Q1 | $448K | Sell |
28,622
-7,195
| -20% | -$113K | ﹤0.01% | 1155 |
|
|
2024
Q4 | $499K | Buy |
35,817
+8,833
| +33% | +$123K | ﹤0.01% | 1276 |
|
|
2024
Q3 | $251K | Buy |
26,984
+9,245
| +52% | +$86K | ﹤0.01% | 1582 |
|
|
2024
Q2 | $165K | Sell |
17,739
-3,251
| -15% | -$30.2K | ﹤0.01% | 1572 |
|
|
2024
Q1 | $208K | Buy |
20,990
+1,870
| +10% | +$18.5K | ﹤0.01% | 1652 |
|
|
2023
Q4 | $61.8K | Buy |
19,120
+8,412
| +79% | +$27.2K | ﹤0.01% | 1837 |
|
|
2023
Q3 | $56.9K | Buy |
10,708
+47
| +0.4% | +$250 | ﹤0.01% | 1702 |
|
|
2023
Q2 | $102K | Buy |
+10,661
| New | +$102K | ﹤0.01% | 1696 |
|
|
2023
Q1 | – | Sell |
-10,379
| Closed | -$154K | – | 1797 |
|
|
2022
Q4 | $154K | Buy |
+10,379
| New | +$154K | ﹤0.01% | 1557 |
|
|
2022
Q2 | – | Sell |
-10,401
| Closed | -$200K | – | 1813 |
|
|
2022
Q1 | $200K | Sell |
10,401
-2,726
| -21% | -$52.4K | ﹤0.01% | 1888 |
|
|
2021
Q4 | $272K | Sell |
13,127
-1,148
| -8% | -$23.8K | ﹤0.01% | 1844 |
|
|
2021
Q3 | $341K | Sell |
14,275
-1,922
| -12% | -$45.9K | ﹤0.01% | 1454 |
|
|
2021
Q2 | $442K | Buy |
16,197
+3,069
| +23% | +$83.8K | ﹤0.01% | 1616 |
|
|
2021
Q1 | $380K | Buy |
13,128
+1,809
| +16% | +$52.4K | ﹤0.01% | 1642 |
|
|
2020
Q4 | $318K | Buy |
+11,319
| New | +$318K | ﹤0.01% | 1570 |
|